GLP2-T 40mg

GLP2-T 40mg Research Peptide Reference Material

ANALYTICAL SPECIFICATION: Lyophilized reference compound supplied at a baseline analytical purity threshold of ≥99%. Verified via independent third-party high-performance liquid chromatography (HPLC) and mass spectrometry (MS) profiling. Strictly for laboratory research use only.

Molecular Architecture & Synthesis Dynamics

GLP2-T 40mg is a highly purified synthetic peptide variant engineered to function as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Structurally, the compound is an acylated peptide consisting of a 39-amino acid sequence. Its primary structure is genetically modified from the native GIP sequence, incorporating a C18 fatty diacid moiety attached via a linker at the lysine residue at position 20. This precise biochemical modification permits heightened stability against proteolytic degradation by dipeptidyl peptidase-4 (DPP-4) in controlled experimental settings.

Mechanism of Action & Receptor Interaction

In vitro assay designs evaluate GLP2-T for its dual binding affinities across human GIP and GLP-1 receptors. As a “twincretin” mimetic pathway, the peptide engages the GIPR and GLP-1R signaling networks, activating intracellular adenylate cyclase. This interaction prompts a downstream cascade resulting in increased cyclic adenosine monophosphate (cAMP) accumulation. In cellular and physiological laboratory models, researchers monitor this dual-agonist activity to study glucose-dependent metabolic responses, intracellular trafficking behaviors, and biased agonism profiles comparing native incretin behaviors to synthetic acylated analogs.

Experimental Validation Vectors

Within established animal models evaluating metabolic regulatory systems, GLP2-T is routinely utilized to map signaling pathways associated with energy homeostasis, nutrient processing, and pancreatic islet cell preservation. Researchers deploy this reference standard to investigate the synergistic effects of simultaneous GIP and GLP-1 receptor activation on central satiety pathways and peripheral gastric motility. The 40mg institutional presentation is specifically optimized for high-throughput automated laboratory screening, lot-to-lot baseline comparisons, and concentration-specific formulation assays.

LABORATORY COMPLIANCE DIRECTIVE: This material is supplied solely as a synthesized reference standard for laboratory evaluation, analytical benchmarking, and in vitro investigation. This product is not a drug, biological material, or therapeutic agent. It is strictly not intended for human consumption, veterinary application, or diagnostic implementation.

References

1. Coskun, T., et al. (2018). “LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.” Molecular Metabolism, 18, 3-14.
2. Frias, J. P., et al. (2021). “Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in metabolic pathway trials.” The Lancet, 398(10295), 143-155.
3. Samms, J. A., et al. (2020). “Dual GIP and GLP-1 receptor agonism preferentially activates specific intracellular signaling cascades in pancreatic beta-cell models.” Biochemical Pharmacology, 178, 114087.